BioTrends Research GroupPosted on:25 Oct 12PharmiWeb.com (press release)Despite initial hesitancy to prescribe biosimilar monoclonal antibodies, the market opportunity for biosimilar versions of rituximab, trastuzumab, cetuximab, and bevacizumab are fo…
Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third QuarterThe Herald | HeraldOnline.comRITUXAN® (rituximab) revenues from our unconsolidated joint business arrangement were $288 million for the quarter, an increase of 8 percent year-…
Clinical Oncology NewsRituximab Maintenance for Elderly With Mantle Cell LymphomaClinical Oncology NewsA one–two punch against mantle cell lymphoma (MCL) in older patients has demonstrated the potential to improve an otherwise dismal prognosis. Resea…
Gilead Sciences Management Discusses Q3 2012 Results – Earnings Call …Seeking AlphaA third study evaluating 1101 with ofatumumab and CLL and two Phase III studies evaluating 1101 in combination with rituximab and with rituximab and bendamustine and i…
Watchful waiting still viable option for follicular lymphomaHealioThe aim was to identify parameters for initiating treatment in the rituximab (Rituxan, Genentech/Idec Pharmaceuticals) era and to determine how parameters for a watchful waiting strategy…
FDA seeks more data from Teva on Treanda cancer drugGlobesThe US Food and Drug Administration (FDA) is asking more data from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) about its first line treatment for non-Hodgkin lymphoma, Treanda, …
Multiple sclerosis DMT approvals "to double by 2012"Pharma Times… will likely constrain the adoption of these potentially high-risk/high-reward therapies by a generally conservative neurologist prescriber base, and forecasts that, together …
22.10.2012 – Warum Frauen besser auf die Therapie ansprechenDKG KrebsgesellschaftNoch besser sind ihre Überlebenschancen offenbar jedoch, wenn sie mit Rituximab behandelt werden. In der aktuellen Studie hatten Patienten mit zuvor unbehandeltem folliku…
Tadias MagazineBattling Cancer in Ethiopia: Interview with Cancer Survivor Tsige Birru-BentiTadias MagazineIn January 2010, I was diagnosed with Lymphoma B-Cell grade 2 cancer. Being in London, where facilities are in place my treatment was on the fast…
Beacon NewsFlashes – October 22, 2012The MDS BeaconPhase 2 Study To Investigate Treatment For Skin Thickening Due To Chronic Graft-Versus-Host Disease – A Phase 2 study comparing Rituxan (rituximab) and Gleevec (imatinib) for the treatment of skin …